Filing Flows › Alnylam Pharmaceuticals (ALNY) › Guidance history
Alnylam Pharmaceuticals (ALNY) guidance history: what it guided and what it reported
Alnylam Pharmaceuticals gave guidance in 10 earnings releases on file since Nov 2, 2023. Of 1 guided period since reported, it met or beat its own guidance once (100%). Revenue: 1 of 1, on average +23.8% against the guided midpoint. Its releases raised guidance 3 times and lowered it once.
Revenue
Met or beat 1 of 1 periods (1 above, 0 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $4.9B–$5.3B (Jan 12, 2026) | — | to be reported | — |
| FY2025 | $3.0B–$3.0B (Oct 30, 2025) | $3.7B | above the range | +23.8% |
GAAP stock-based compensation
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $330M–$380M (Jul 30, 2026) | — | to be reported | — |
| FY2025 | $345M–$375M (Jul 31, 2025) | — | — | — |
The latest quarter
Alnylam Pharmaceuticals, Q3 2026: revenue $1.5B (+17% year over year), operating margin 23.7%, net earnings $2.2B, operating cash flow $341M. The chart follows the revenue to costs, profit and cash.
Questions
Does Alnylam Pharmaceuticals beat its guidance?
Alnylam Pharmaceuticals gave guidance in 10 earnings releases on file since Nov 2, 2023. Of 1 guided period since reported, it met or beat its own guidance once (100%). Revenue: 1 of 1, on average +23.8% against the guided midpoint.
How often does Alnylam Pharmaceuticals raise guidance?
Its earnings releases raised guidance 3 times and lowered it once since Nov 2, 2023.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.